Displaying all 2 publications

Abstract:
Sort:
  1. Fulltext Autoclave-assisted synthesis of AgNPs in Z. officinale extract and assessment of their cytotoxicity, antibacterial and antioxidant activities
    Kalantari K, Afifi AM, Moniri M, Moghaddam AB, Kalantari A, Izadiyan Z
    IET Nanobiotechnol, 2019 May;13(3):262-268.
    PMID: 31053688 DOI: 10.1049/iet-nbt.2018.5066
    In this study, the authors synthesised silver nanoparticles (AgNPs) using autoclave as a simple, unique and eco-friendly approach. The effect of Zingiber officinale extract was evaluated as a reducing and stabiliser agent. According to transmission electron microscopy results, the AgNPs were in the spherical shape with a particle size of ∼17 nm. The biomedical properties of AgNPs as antibacterial agents and free radical scavenging activity were estimated. Synthesised AgNPs showed significant 1,1-diphenyl-2-picryl-hydrazyl free radical scavenging. Strong bactericidal activity was shown by the AgNPs on Gram-positive and Gram-negative bacteria. A maximum inhibition zone of ∼14 mm was obtained for epidermidis at a concentration of 60 μg/ml for sample fabricated at 24 h. The AgNPs also showed a significant cytotoxic effect against MCF-7 breast cancer cell lines with an half maximal inhibitory concentration value of 62 μg/ml in 24 h by the MTT assay. It could be concluded that Z. officinale extract can be used effectively in the production of potential antioxidant and antimicrobial AgNPs for commercial application.
  2. Global systematic review of primary immunodeficiency registries
    Abolhassani H, Azizi G, Sharifi L, Yazdani R, Mohsenzadegan M, Delavari S, et al.
    Expert Rev Clin Immunol, 2020 07;16(7):717-732.
    PMID: 32720819 DOI: 10.1080/1744666X.2020.1801422
    INTRODUCTION: During the last 4 decades, registration of patients with primary immunodeficiencies (PID) has played an essential role in different aspects of these diseases worldwide including epidemiological indexes, policymaking, quality controls of care/life, facilitation of genetic studies and clinical trials as well as improving our understanding about the natural history of the disease and the immune system function. However, due to the limitation of sustainable resources supporting these registries, inconsistency in diagnostic criteria and lack of molecular diagnosis as well as difficulties in the documentation and designing any universal platform, the global perspective of these diseases remains unclear.

    AREAS COVERED: Published and unpublished studies from January 1981 to June 2020 were systematically reviewed on PubMed, Web of Science and Scopus. Additionally, the reference list of all studies was hand-searched for additional studies. This effort identified a total of 104614 registered patients and suggests identification of at least 10590 additional PID patients, mainly from countries located in Asia and Africa. Molecular defects in genes known to cause PID were identified and reported in 13852 (13.2% of all registered) patients.

    EXPERT OPINION: Although these data suggest some progress in the identification and documentation of PID patients worldwide, achieving the basic requirement for the global PID burden estimation and registration of undiagnosed patients will require more reinforcement of the progress, involving both improved diagnostic facilities and neonatal screening.

Related Terms
    Try searching for something
Filters
Contact Us

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links